- Trials with a EudraCT protocol (59)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
59 result(s) found for: Cytochrome P450.
Displaying page 1 of 3.
EudraCT Number: 2006-005416-28 | Sponsor Protocol Number: LM0601 | Start Date*: 2006-12-19 |
Sponsor Name:Danish University of Pharmaceutical Sciences | ||
Full Title: Cytochrome P450 metabolism of lidokain in human skin (Cytochrom P450 metabolisme af lidokain i human hud) | ||
Medical condition: How lidocaine is metabolised in the skin | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001440-18 | Sponsor Protocol Number: IACI2016 | Start Date*: 2018-05-30 |
Sponsor Name:university medical center utrecht | ||
Full Title: Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in cystic fibrosis patients and healthy controls | ||
Medical condition: cystic fibrosis and healthy subjects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023749-30 | Sponsor Protocol Number: PKCTnrCSL01 | Start Date*: 2011-10-20 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Studio PKCT - Pharmacokinetics of chemotherapy when given concurrently with antiretroviral (Protocol no. CSL01). | |||||||||||||
Medical condition: patients with Hodgkin lymphoma and non-Hodgkin's lymphoma and HIV infection. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000082-41 | Sponsor Protocol Number: 2021-0486 | Start Date*: 2022-03-31 |
Sponsor Name:Fundación para la Investigación en Urología | ||
Full Title: Impact of pitavastatin use in prostate cancer patients treated with new generation androgen therapy: multicenter clinical trial | ||
Medical condition: We propose a multicenter, prospective, randomized, single-blind clinical trial, without conflict of interest, to determine the clinical benefit of statins (Pitavastatin 2 mg) in prostate cancer pa... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000229-24 | Sponsor Protocol Number: RD.06.SPR.201593 | Start Date*: 2021-02-23 | |||||||||||
Sponsor Name:Galderma S.A. | |||||||||||||
Full Title: An Open-label Drug-Drug Interaction Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Severe Atopic Dermatitis | |||||||||||||
Medical condition: Moderate-to-severe atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008895-15 | Sponsor Protocol Number: HCL/P 2008.537/38 | Start Date*: 2009-02-16 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Influence de l'introduction du sirolimus sur la balance inflammatoire chez le transplanté rénal | |||||||||||||
Medical condition: Transplantation rénale | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012802-38 | Sponsor Protocol Number: UMCNONCO200903 | Start Date*: 2009-07-01 |
Sponsor Name:University Medical Centre Nijmegen St Radboud | ||
Full Title: Evaluation of the activity of temsirolimus with FLT-PET in patients with renal cell cancer | ||
Medical condition: advanced (stage IV or recurrent disease) RCC | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-002192-32 | Sponsor Protocol Number: UKSH-A105 | Start Date*: 2006-07-28 |
Sponsor Name:Univeristy Hospital Schleswig-Holstein | ||
Full Title: Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma | ||
Medical condition: non-resectable metastatic malignant melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2008-003169-19 | Sponsor Protocol Number: CYC-201 | Start Date*: 2009-11-09 | |||||||||||
Sponsor Name:Sigmoid Pharma Ltd | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapusle Formulation of Ciclosporin (CyCol™) in the Treatment of Ulcerative Colitis | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001559-20 | Sponsor Protocol Number: 95195608 | Start Date*: 2007-04-17 |
Sponsor Name:Cliniques Universitaires Saint-Luc | ||
Full Title: Steady-state pharmacokinetics of high dose acetaminophen inpost-op children. Rational use of N-acetyl cysteine for prevention of liver toxicity related to cumulative doses. | ||
Medical condition: Major surgery when the use of paracetamol is required for pain release | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2022-003265-38 | Sponsor Protocol Number: PTC743-NEU-005-FA | Start Date*: 2022-10-22 |
Sponsor Name:PTC Therapeutics, Inc. | ||
Full Title: An Open-Label Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Vatiquinone in Children With Friedreich Ataxia Younger Than 7 Years of Age | ||
Medical condition: Friedreich Ataxia | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2005-004321-26 | Sponsor Protocol Number: 1100.1452 | Start Date*: 2006-02-17 |
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | ||
Full Title: A Case-Control Toxicogenomics Study to identify Unique Genetic Polymorphisms in Patients who have experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity within the First 8 weeks of Nev... | ||
Medical condition: The patient population for this study will be comprised of patients with HIV-1 infection who have taken or are currently taking nevirapine and who have (cases) or have not (controls) experienced sy... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023776-52 | Sponsor Protocol Number: Lisette-1 | Start Date*: 2011-01-19 | |||||||||||
Sponsor Name: | |||||||||||||
Full Title: Optimizing tamoxifen therapy through the induction of CYP3A4, CYP2C and CYP2D6 mediated metabolism | |||||||||||||
Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000686-68 | Sponsor Protocol Number: B4Z-JE-LYDA | Start Date*: 2021-12-02 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Long-Term Extension, Open-Label Study of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder | |||||||||||||
Medical condition: Attention-Deficit/Hyperactivity Disorder (AD/HD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001151-39 | Sponsor Protocol Number: A1501081 | Start Date*: 2012-03-06 |
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | ||
Full Title: An Open Label, Intravenous to Oral Switch, Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Immunocompromised Adolescents Aged 12 to <17 Years who ar... | ||
Medical condition: Invasive fungal infections | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-004698-39 | Sponsor Protocol Number: 1188.31 | Start Date*: 2006-02-03 |
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | ||
Full Title: Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of oral administered RTV-boosted BILR 355 (75 mg and 150 mg twice daily... | ||
Medical condition: This randomized, placebo-controlled, double-blind trial will be conducted in HIV-1 infected patients who have experienced virological failure with at least one NNRTI-based HAART regimen. The treatm... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004044-28 | Sponsor Protocol Number: AKF-396 | Start Date*: 2020-12-18 | |||||||||||
Sponsor Name:University of Southern Denmark | |||||||||||||
Full Title: Flucloxacillin as an inducer of CYP-enzymes | |||||||||||||
Medical condition: Healthy volunteers. (Flucloxacillin is used against infections caused by beta-lactamase-producing organisms) Testing for drug-drug interactions caused by flucloxacillin | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001235-12 | Sponsor Protocol Number: GULLIVER-2 | Start Date*: 2021-07-20 | |||||||||||
Sponsor Name:Galecto Biotech AB | |||||||||||||
Full Title: GULLIVER-2 - a single (open-label) and repeat dose (randomised, placebo-controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with he... | |||||||||||||
Medical condition: Healthy subjects (for study Parts 1 and 3) and patients with hepatic impairment (Child Pugh B and Child Pugh C) (cirrhosis) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002426-28 | Sponsor Protocol Number: 81896-PREDICTAM | Start Date*: 2022-11-14 |
Sponsor Name:Erasmus MC Cancer Institute | ||
Full Title: Predicting an accurate tamoxifen dose: a feasibility study in patients with hormone positive breast cancer | ||
Medical condition: Hormone positive breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020219-35 | Sponsor Protocol Number: | Start Date*: 2011-07-18 |
Sponsor Name:Royal Brompton & Harefield NHS Foundation Trust | ||
Full Title: Evaluating the benefit of additional platelet inhibition in acute coronary syndrome patients with high platelet reactivity undergoing PCI | ||
Medical condition: Cardiovascular disease - Acute coronary syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.